Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Titel:
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Auteur:
Lentzsch, Suzanne O'Sullivan, Amy Kennedy, Ryan C. Abbas, Mohammad Dai, Lijun Pregja, Silvana Lalo Burt, Steve Boyiadzis, Michael Roodman, G. David Mapara, Markus Y. Agha, Mounzer Waas, John Shuai, Yongli Normolle, Daniel Zonder, Jeffrey A.